Format

Send to

Choose Destination
Br J Haematol. 2019 Apr;185(2):284-288. doi: 10.1111/bjh.15799. Epub 2019 Feb 19.

Clinical and biological features of paediatric acute myeloid leukaemia (AML) with primary induction failure in the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study.

Author information

1
Department of Paediatrics, Osaka University Graduate School of Medicine, Osaka, Japan.
2
Clinical Research Centre, National Hospital Organization Nagoya Medical Centre, Aichi, Japan.
3
Division of Paediatrics, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
4
Department of Paediatrics, National Hospital Organization, Kyusyu Cancer Centre, Fukuoka, Japan.
5
Department of Clinical Biostatistics, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
6
Division of Leukaemia and Lymphoma, Children's Cancer Centre, National Centre for Child Health and Development, Tokyo, Japan.
7
Department of Paediatrics, Yokohama City University School of Medicine, Yokohama, Japan.
8
Department of Paediatrics, Osaka National Hospital, Osaka, Japan.
9
Department of Paediatrics, Okayama University Graduate School of Medicine, Okayama, Japan.
10
Department of Paediatrics, Mie University Graduate School of Medicine, Tsu, Japan.
11
Department of Haematology/Oncology, Gunma Children's Medical Centre, Shibukawa, Japan.
12
Department of Paediatrics, Tokai University School of Medicine, Isehara, Japan.
13
Department of Paediatrics, St. Luke's International Hospital, Tokyo, Japan.
14
Department of Paediatrics and Developmental Biology, Graduate School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan.
15
Department of Paediatrics, Shiga University of Medical Science, Shiga, Japan.
16
Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Abstract

The prognosis of paediatric acute myeloid leukaemia (AML) with primary induction failure (PIF) is extremely poor, and effective treatment strategies have not been established. We investigated the clinical and biological features of paediatric AML patients with PIF registered to the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study. The 3-year overall survival rate of the 41 PIF patients was 19.0%. High leucocyte count, M7 morphology, and unfavourable genetic aberrations, such as FLT3-internal tandem duplication, NUP98-NSD1 and high MECOM or PRDM16 expression, were risk factors for PIF. More effective treatment strategies based on leukaemia biology need to be urgently explored.

KEYWORDS:

acute myeloid leukaemia; childhood; genetic alteration; haematopoietic stem cell transplantation; primary induction failure

PMID:
30784060
DOI:
10.1111/bjh.15799

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center